CL2022002813A1 - Semaglutida para el tratamiento de esteatohepatitis no alcoholica. - Google Patents

Semaglutida para el tratamiento de esteatohepatitis no alcoholica.

Info

Publication number
CL2022002813A1
CL2022002813A1 CL2022002813A CL2022002813A CL2022002813A1 CL 2022002813 A1 CL2022002813 A1 CL 2022002813A1 CL 2022002813 A CL2022002813 A CL 2022002813A CL 2022002813 A CL2022002813 A CL 2022002813A CL 2022002813 A1 CL2022002813 A1 CL 2022002813A1
Authority
CL
Chile
Prior art keywords
treatment
semaglutide
alcoholic steatohepatitis
glp
directed
Prior art date
Application number
CL2022002813A
Other languages
English (en)
Inventor
Martin Linder
Mads Sundby Palle
Lars Holm Damgaard
Morten Hansen
Carl Richard Torstenson
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2022002813A1 publication Critical patent/CL2022002813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors

Abstract

La presente invención se dirige al uso del agonista del receptor de GLP-1 semaglutida en la terapia médica para el tratamiento de la esteatohepatitis no alcohólica.
CL2022002813A 2020-04-27 2022-10-12 Semaglutida para el tratamiento de esteatohepatitis no alcoholica. CL2022002813A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20171536 2020-04-27
EP20173341 2020-05-06

Publications (1)

Publication Number Publication Date
CL2022002813A1 true CL2022002813A1 (es) 2023-04-21

Family

ID=75660049

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002813A CL2022002813A1 (es) 2020-04-27 2022-10-12 Semaglutida para el tratamiento de esteatohepatitis no alcoholica.

Country Status (13)

Country Link
US (3) US11478533B2 (es)
EP (1) EP4142770A1 (es)
JP (1) JP7393563B2 (es)
KR (1) KR20230015884A (es)
CN (1) CN115461072A (es)
AU (1) AU2021262447A1 (es)
BR (1) BR112022020643A2 (es)
CA (1) CA3174964A1 (es)
CL (1) CL2022002813A1 (es)
IL (1) IL297273A (es)
MX (1) MX2022013174A (es)
TW (1) TW202140064A (es)
WO (1) WO2021219543A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138874A1 (en) 2020-04-24 2023-03-01 Boehringer Ingelheim International GmbH Glucagon analogues as long-acting glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
TW202333774A (zh) * 2021-12-01 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1和gip受體雙重激動劑的醫藥組成物及其用途
CN114469877A (zh) * 2022-01-28 2022-05-13 兰州积石药业有限公司 一种司美格鲁肽植入剂及其制备方法
WO2024017139A1 (zh) * 2022-07-20 2024-01-25 成都海博为药业有限公司 一种含有glp-1受体激动剂类似物的药物组合物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6114297B2 (ja) 2011-11-11 2017-04-12 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤およびその使用
EP2776405A1 (en) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
EA201400990A1 (ru) 2012-04-06 2015-01-30 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2
CA2911932A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CA2911926A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015416A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
KR20160005364A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
HUE039446T2 (hu) 2014-03-17 2018-12-28 Pfizer Diacilglicerol-aciltranszferáz-2 inhibitorok metabolikus rendellenességek és kapcsolódó rendellenességek kezelésében történõ alkalmazásra
EP3197448B1 (en) 2014-09-24 2019-04-24 Gilead Sciences, Inc. Methods of treating liver disease
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EP3368556B1 (en) 2015-10-28 2024-04-10 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
WO2017091627A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
JP2018536661A (ja) 2015-11-25 2018-12-13 ギリアド アポロ， エルエルシー トリアゾールａｃｃ阻害剤およびその使用
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
BR112018067408A2 (pt) 2016-03-02 2018-12-26 Gilead Apollo Llc formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
CA3021140A1 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
EP3463373A4 (en) 2016-05-25 2020-04-22 Akarna Therapeutics, Ltd. COMBINATIONS USING FARNESOID X RECEPTOR (FXR) MODULATORS
MX2018014743A (es) 2016-06-03 2019-04-11 Chemocentryx Inc Metodo para tratar fibrosis hepatica.
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
EP3518918A4 (en) 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
WO2018071528A1 (en) 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
AU2017356160A1 (en) 2016-11-11 2019-05-23 Gilead Sciences, Inc. Methods of treating liver disease
CN110198708B (zh) 2017-01-27 2022-09-20 基恩菲特公司 用于组合疗法的药物组合物
KR102424042B1 (ko) 2017-03-03 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Acc 억제제 및 그의 고체 형태를 제조하는 방법
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
WO2018183342A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
KR20190132515A (ko) 2017-04-12 2019-11-27 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하는 방법
WO2018193007A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
TW201908483A (zh) 2017-06-02 2019-03-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法
US10495648B2 (en) 2017-06-13 2019-12-03 Gilead Sciences, Inc. Methods of treating liver fibrosis
JP7273022B2 (ja) 2017-07-19 2023-05-12 バイオ―ラッド ヨーロッパ ゲーエムベーハー 非アルコール性脂肪性肝炎及び肝線維症ステータスを同時に評価するバイオマーカの組み合わせ
WO2019030268A1 (en) 2017-08-09 2019-02-14 Sanofi GLP-1 / GLUCAGON RECEPTOR AGONISTS FOR THE TREATMENT OF HEPATIC STEATOSIS AND STÉATOHÉPATITE
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
KR20220103807A (ko) 2017-10-06 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법
CN111801140A (zh) 2018-01-17 2020-10-20 康涅狄格大学 治疗糖尿病、肝炎和/或炎症性肝病的方法
EP3755334A4 (en) 2018-02-21 2022-03-23 Melior Pharmaceuticals I, Inc. TREATMENT OF LIVER DISEASES
WO2019173505A1 (en) 2018-03-06 2019-09-12 Zafgen, Inc. Methods of treating disorders related to glycemic control
US20210069286A1 (en) 2018-04-09 2021-03-11 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage
JP2021522247A (ja) 2018-04-24 2021-08-30 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 肝疾患における好中球エラスターゼ阻害薬の使用
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
CA3097939A1 (en) 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
US11081516B2 (en) 2018-08-10 2021-08-03 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Display screen, electronic device and method for three-dimensional feature recognition
EP3843740A1 (en) 2018-08-31 2021-07-07 Pfizer Inc. Combinations for treatment of nash/nafld and related diseases
BR112021006598A2 (pt) 2018-10-26 2021-07-06 Novo Nordisk As composição farmacêutica líquida, e, kit
US20200155487A1 (en) 2018-11-16 2020-05-21 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
JP2022507644A (ja) 2018-11-16 2022-01-18 サイマベイ・セラピューティクス・インコーポレイテッド Ｎａｆｌｄおよびｎａｓｈの併用治療
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
AU2020234929B2 (en) 2019-03-11 2023-09-14 Gilead Sciences, Inc. Formulations of a compound and uses thereof
CN115135305A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 药物制剂
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine

Also Published As

Publication number Publication date
CN115461072A (zh) 2022-12-09
IL297273A (en) 2022-12-01
WO2021219543A1 (en) 2021-11-04
MX2022013174A (es) 2022-11-30
KR20230015884A (ko) 2023-01-31
JP2023516505A (ja) 2023-04-19
TW202140064A (zh) 2021-11-01
CA3174964A1 (en) 2021-11-04
US20240075106A1 (en) 2024-03-07
JP7393563B2 (ja) 2023-12-06
US11478533B2 (en) 2022-10-25
BR112022020643A2 (pt) 2022-12-13
US20210330748A1 (en) 2021-10-28
EP4142770A1 (en) 2023-03-08
AU2021262447A1 (en) 2022-11-03
US20230023012A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
CL2022002813A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcoholica.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2017002526A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015)
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2017000191A1 (es) Método
UY35465A (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2021001722A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CR20180433A (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
PH12016502353A1 (en) Pharmaceutical composition
AU2019262169B2 (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORy) and pharmaceutical uses thereof
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
MX2020003563A (es) Anticuerpo anti-pacap.
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
ECSP22085947A (es) Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
BR112019006174A2 (pt) proteina terapêutica